Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
HRS-9821 is being developed as an add-on maintenance treatment for COPD, regardless of background therapy, and could complement GSK's anti-IL-5 antibody Nucala (mepolizumab), which recently claimed its first approval as a treatment for the serious respiratory disease, as well as older COPD drugs like Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
They appear to make them work better
Get started with Hers Interested in trying Hers
Research Applications Triple hormone receptor (GLP-1/GIP/Glucagon) research Metabolic rate and energy expenditure studies Advanced obesity and weight regulation biology Insulin sensitivity and glucose metabolism research Combination incretin pathway investigations Quality Specifications Purity: 98% (HPLC verified) Compound: Retatrutide Molecular Weight: ~4.9 kDa Form: Lyophilized powder Origin: Made in the USA Testing: Third-party tested in a US laboratory Storage: -20C, protect from light COA: Batch-specific, ISO-accredited laboratory Frequently Asked Questions Q: What makes Retatrutide unique
US$ 23.16
US$ 23.34
US$ 21.30
US$ 23.69
US$ 22.03
